Contineum Therapeutics Overview
Latest P/E ratio for Contineum Therapeutics: -7.82 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-7.82
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Contineum Therapeutics (CTNM) currently reports a P/E ratio of -7.82. That is below the sector sector average of 35.6. Use the charts on this page to explore Contineum Therapeutics's P/E ratio history and peer comparisons.
Contineum Therapeutics's P/E ratio of -7.82 is lower than the its sector sector average of 35.6. That is roughly 122.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Contineum Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -7.82, CTNM can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -7.82, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 35.6. From there, open related valuation or income-statement pages for Contineum Therapeutics, and consider following CTNM for alerts when major investors trade the stock.
